Journal of Infection and Public Health
Volume 1, Issue 2 , Pages 105-112 , 2008

Unexpected induction of resistant Pseudomonas aeruginosa biofilm to fluoroquinolones by diltiazem: A new perspective of microbiological drug–drug interaction

Received 15 August 2008 ,Revised 21 October 2008 ,Accepted 22 October 2008.

References 

  1. Romero M, Sanchez I, Pujol MD. New advances in the field of calcium channel antagonists: cardiovascular effects and structure–activity relationships. Curr Med Chem – Cardiovasc Hematol Agents. 2003;1(2):113–141
  2. Budriesi R, Cosimelli B, Ioan P, Carosati E, Ugenti MP, Spisani R. Diltiazem analogues: the last ten years on structure activity relationships. Curr Med Chem. 2007;14(3):279–287
  3. Blickle JF. Management of hypertension in elderly diabetic patients. Diabetes Metab. 2005;2:5S82–91
  4. Palmer RJ, Stoodley P. Biofilms 2007: broadened horizons and new emphases. J Bacteriol. 2007;189(22):7948–7960
  5. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol. 2002;56:187–209
  6. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005;25(10):1353–1364
  7. Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade, multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol. 2007;10(5):436–440
  8. Fux CA, Stoodley P, Hall-Stoodley L, Costerton JW. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther. 2003;1(4):667–683
  9. Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol. 2005;13(1):7–10
  10. Mah T, Pitts B, Pellock B, Walker GC, Stewart PS, O’Toole GA. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature. 2003;426(6964):306–310
  11. Algun U, Arisoy A, Gunduz T, Ozbakkaloglu B. The resistance of Pseudomonas aeruginosa strains to fluoroquinolone group of antibiotics. Indian J Med Microbiol. 2004;22(2):112–114
  12. Auckenthaler R, Michea-Hamzehpour M, Pechere JC. In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother. 1986;17(Suppl. B):29–39
  13. Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother. 2007;51(11):4062–4070
  14. Huang SS, Lee SC, Lee N, See LC, Tsai MH, Shieh WB. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections. J Microbiol Immunol Infect. 2007;40(2):134–140
  15. Rogues AM, Dumartin C, Amadeo B, Venier AG, Marty N, Parneix P, et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol. 2007;28(12):1389–1395
  16. Riedinger JL, Robbins LJ. Prevention of iatrogenic illness: adverse drug reactions and nosocomial infections in hospitalized older adults. Clin Geriatr Med. 1998;14(4):681–698
  17. Aspa J, Rajas O, Rodriguez de Castro F, Blanquer J, Zalacain R, Fenoll A, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis. 2004;38(6):787–798
  18. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51(10):3568–3573
  19. Engelhart ST, Hanses-Derendorf L, Exner M, Kramer MH. Prospective surveillance for healthcare-associated infections in German nursing home residents. J Hosp Infect. 2005;60(1):46–50
  20. Gavazzi G, Herrmann F, Krause KH. Aging and infectious diseases in the developing world. Clin Infect Dis. 2004;39(1):83–91
  21. Donowitz GR, Cox HL. Bacterial community-acquired pneumonia in older patients. Clin Geriatr Med. 2007;23(3):515–534
  22. David MZ, Crawford SE, Boyle-Vavra S, Hostetler MA, Kim DC, Daum RS. Contrasting pediatric and adult methicillin-resistant Staphylococcus aureus isolates. Emerg Infect Dis. 2006;12(4):631–637
  23. Gutiérrez F, Masiá M, Mirete C, Soldán B, Carlos Rodríguez J, Padilla S, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect. 2006;53(3):166–174
  24. Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Stretching the mutant prevention concentration (MPC) beyond its limits. J Antimicrob Chemother. 2003;51(6):1323–1325
  25. Takahashi P, Trang N, Chutka D, Evans J. Antibiotic prescribing and outcomes following treatment of symptomatic urinary tract infections in older women. J Am Med Dir Assoc. 2002;3(6):352–355
  26. Sanchez-Romero I, Cerenado E, Cuevas O, Garcia-Escribano N. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: second national study (2003). Rev Esp Quimioter. 2007;20:222–229
  27. Alou L, Gimenez MJ, Sevillano D, Aguilar L, Cafini F, Echeverria O, et al. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. J Antimicrob Chemother. 2006;58(2):349–358
  28. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003;49(2):53–70
  29. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005;4(Suppl. 2):49–54
  30. Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalized patients with community-acquired pneumonia: pharmacodynamic target attainment study using north American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents. 2005;26(2):120–125
  31. Wang CY, Jerng JS, Chen KY, Lee LN, Yu CJ, Hsueh PR, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalized patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect. 2006;12(1):63–68
  32. Zalacain R, Torres A, Celis R, Blanquer J, Aspa J, Esteban L, et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J. 2003;21(2):294–302
  33. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American urinary tract infection collaborative alliance (NAUTICA). Int J Antimicrob Agents. 2006;27(6):468–475
  34. Akiyama S, Gottesman MM, Hanover JA, Fitzgerald DJ, Willingham MC, Pastan I. Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. J Cell Physiol. 1984;120(3):271–279
  35. Cohn RC, Rudzienski L, Putnam RW. Verapamil-tobramycin synergy in Pseudomonas cepacia but not Pseudomonas aeruginosa in vitro. Chemotherapy. 1995;41(5):330–333
  36. Kumar KA, Ganguly K, Mazumdar K, Dutta NK, Dastidar SG, Chakrabarty AN. Amlodipine: a cardiovascular drug with powerful antimicrobial property. Acta Microbiol Pol. 2003;52(3):285–292
  37. McCoy WF, Bryers JD, Robbins J, Costerton JW. Observations of fouling biofilm formation. Can J Microbiol. 1981;27(9):910–917
  38. Pedersen K. Method for studying microbial biofilms in flowing-water systems. Appl Environ Microbiol. 1982;43(1):6–13
  39. Marrie TJ, Costerton JW. Scanning and transmission electron microscopy of in situ bacterial colonization of intravenous and intraarterial catheters. J Clin Microbiol. 1984;19(5):687–693
  40. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95–108
  41. Walker TS, Bais HP, Déziel E, Schweizer HP, Rahme LG, Fall R, et al. Pseudomonas aeruginosa-plant root interactions: pathogenicity, biofilm formation, and root exudation. Plant Physiol. 2004;134:320–331
  42. Eickelberg O, Roth M, Mussmann R, Rudiger JJ, Tamm M, Perruchoud AP, et al. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-kB in primary human vascular smooth muscle cells. Circulation. 1999;99:2276–2282
  43. Sarkisova S, Patrauchan MA, Berglund D, Nivens DE, Franklin MJ. Calcium-induced virulence factors associated with the extracellular matrix of mucoid Pseudomonas aeruginosa biofilms. J. Bacteriol. 2005;187(13):4327–4337

☆ This manuscript was presented in part at the Design of Medical Devices conference April 2008, University of Minnesota, Minneapolis, MN. “A High-Throughput Biofilm Model of Treatment Efficacy for Pseudomonas aeruginosa Device Associated Infections”. Acceptance No. 027535.

PII: S1876-0341(08)00030-0

doi: 10.1016/j.jiph.2008.10.004

Journal of Infection and Public Health
Volume 1, Issue 2 , Pages 105-112 , 2008

Article Tools

* Image Usage & Resolution